文献速递肿瘤 PET/CT核素与放射性配体治疗

混合示踪剂用于膀胱癌前哨淋巴结检测的前瞻性临床研究——SPECT/CT显示前哨淋巴结者可否替代盆腔淋巴结清扫

Prospective clinical study of sentinel node detection in bladder cancer using a hybrid tracer - Towards replacement of pelvic lymph node dissection in cases with sentinel node visualization on SPECT/CT?
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2025-04-04

30例肌层浸润性膀胱癌或极高危非肌层浸润性膀胱癌患者接受经尿道瘤周注射吲哚菁绿(ICG)-99mTc-纳米胶体行前哨淋巴结示踪,术前SPECT/CT在19例中显示31枚前哨淋巴结,11例(36.7%)未显示;5/35枚前哨淋巴结(14.2%)病理阳性且补充盆腔淋巴结清扫未发现额外阳性淋巴结,前哨淋巴结未显示者淋巴结转移风险更高、预后更差。

要点

  • 术前SPECT/CT在多数患者中显示前哨淋巴结,11例(36.7%)未显示。
  • 5/35枚前哨淋巴结(14.2%)肿瘤阳性,补充盆腔淋巴结清扫未发现额外阳性淋巴结。
  • 前哨淋巴结未显示者淋巴结转移风险更高且预后更差。

核心结论

  • 术前SPECT/CT在多数患者中实现前哨淋巴结显示。
  • 前哨淋巴结未显示的患者淋巴结转移风险增加且预后更差。
  • 前哨淋巴结有转移的患者在补充盆腔淋巴结清扫中未发现额外淋巴结转移。

研究设计与样本

  • 前瞻性研究纳入30例极高危非肌层浸润性膀胱癌或肌层浸润性膀胱癌、cN0M0(接受或不接受新辅助全身治疗)并计划行根治性膀胱切除加盆腔淋巴结清扫的患者。
  • 患者接受四至六次经尿道瘤周注射ICG-99mTc-纳米胶体至膀胱行前哨淋巴结示踪。
  • 术前一天行淋巴显像和SPECT/CT,术中通过荧光(手持相机或荧光腹腔镜)和放射引导(手持、腹腔镜或DROP-IN探头)检测前哨淋巴结。
  • 切除标本包括前哨淋巴结和盆腔淋巴结清扫组织,均由病理学家分析;记录示踪剂注射相关并发症,采用Kaplan-Meier生存曲线分析癌症特异性生存和总生存。

主要发现

  • SPECT/CT显示19例患者共31枚前哨淋巴结,11例(36.7%)未显示前哨淋巴结。
  • 术中基于荧光信号在3例患者中额外识别4枚前哨淋巴结;1例开放膀胱切除术患者离体评估盆腔淋巴结清扫标本发现1枚额外放射性前哨淋巴结。
  • 盆腔淋巴结清扫共检出592枚淋巴结(中位17枚/患者);35枚前哨淋巴结中5枚(14.2%)病理阳性且补充盆腔淋巴结清扫未发现额外肿瘤阳性淋巴结;592枚淋巴结中3枚(0.5%)肿瘤阳性(2例为前哨淋巴结未显示患者)。
  • 平均随访82个月(SD ± 7.1个月)时17%患者死于疾病;前哨淋巴结未显示且伴淋巴结转移的2例患者生存率为0%,低于前哨淋巴结阳性患者的75%;24例pN0患者中8%死亡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Nodal staging in patients with muscle invasive bladder cancer (MIBC) or very high risk non-muscle invasive bladder cancer (vhNMIBC) aids to predict survival. The sentinel node (SN) procedure holds the promise to identify the diagnostically relevant first tumor-draining nodes while limiting the complication rate associate with a pelvic lymph node dissection (PLND), still considered the gold standard of nodal staging. Following an initial technical feasibility study, we prospectively evaluated the clinical impact of using peri-tumoral injections with the hybrid tracer indocyanine green (ICG)-99mTc-nanocolloid for SN procedures in bladder cancer. METHODS: A total of 30 patients with vhNMIBC or MIBC, cN0M0 (with or without neo-adjuvant systemic therapy) scheduled for radical cystectomy with pelvic lymph node dissection (PLND) were enrolled in a prospective study. Patients received four to six transurethral peritumoral injections of ICG-99mTc-nanocolloid into the bladder for SN tracing. Preoperative lymphoscintigraphy and Single Photon Emission Computed Tomography (SPECT)/CT was performed the day before surgery. The intraoperative detection of SNs was supported by both fluorescence (utilizing a hand-held camera or fluorescence laparoscope) and radio-guidance (using hand-held, laparoscopic or DROP-IN probe tracing). Resected specimens, comprising both SNs and PLND tissue, were analyzed by the pathologist. Complications related to the tracer injection were documented and cancer-specific survival (CSS) and overall survival (OS) were studied using Kaplan-Meier survival curves. RESULTS: SPECT/CT imaging revealed 31 SNs in 19 patients with non-visualization of SN in 11 patients (36.7%). During surgery, 4 additional SNs were identified based on fluorescent signals in 3 patients. In 1 patient who underwent open cystectomy, ex vivo evaluation of the PLND-specimen revealed an additional radioactive SN. The PLND yielded 592 lymph nodes (LNs; median 17 LNs/patient). In 5 out of 35 SNs (14.2%; no additional tumor positive LN in complementary PLND) and 3 out of 592 LNs (0.5%; 2 patients with non-visualization of SN) were identified as tumor-positive upon pathological evaluation. At mean follow up of 82 months (SD ± 7.1 months) 17% of patients died of disease. The 2 patients with non-visualization of SN and nodal metastases (0%) did worse than SN positive patients (75%). Of the 24 patients classified as pN0 8% died. CONCLUSIONS: Preoperative SN-visualization on SPECT/CT was achieved in the majority of patients. Patients with SN non-visualization had an increased risk of nodal metastases and poorer outcome. In patients with metastases in the SN no additional nodal metastases were found in the complementary PLND.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. van Gennep EJ, Pisano G, KleinJan GH, et al. Prospective clinical study of sentinel node detection in bladder cancer using a hybrid tracer - Towards replacement of pelvic lymph node dissection in cases with sentinel node visualization on SPECT/CT? Eur J Nucl Med Mol Imaging. 2025. PMID: 40183956. doi:10.1007/s00259-025-07240-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。